Dissecting The Rhetoric Vs. Reality Of Trump’s Tough Talk On Drug Prices
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
How A Drugmaker Turned The Abortion Pill Into A Rare-Disease Profit Machine
An abortion drug invented decades ago is being used to treat Cushing’s syndrome — and it’s bringing in tens of millions of dollars a year.
FDA Head Vows To Tackle High Drug Prices And Drugmakers ‘Gaming The System’
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
Trump’s Budget Proposal Swings At Drug Prices With A Glancing Blow
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
FDA Chief Says He’s Open To Rethinking Incentives On Orphan Drugs
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Experts Tell Congress How To Cut Drug Prices. We Give You Some Odds.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
Patients With Rare Diseases And Congress Square Off Over Orphan Drug Tax Credits
The House and Senate want to reduce or eliminate federal tax credits for “orphan drugs” used to treat rare diseases, but patients are fighting against the plan.
Heated And Deep-Pocketed Battle Erupts Over 340B Drug Discount Program
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
Medicare Seeks Comment On Ways To Cut Costs Of Part D Drugs
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
Pressure Builds To Cut Medicare Patients In On Prescription Deals
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.
House Republicans Aim To Yank Tax Credits For Orphan Drugs
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
Timeline: Insulin Market Under Scrutiny
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers — middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
Flurry Of Federal And State Probes Target Insulin Drugmakers And Pharma Middlemen
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
Without Price Breaks, Rural Hospitals Struggle To Stock Costly, Lifesaving Drugs
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
FDA Moves To Guard Against Abuse Of ‘Orphan Drug’ Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
Hospitals Slashed Use Of Two Heart Drugs After Huge Price Hikes
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
Congress Squares Off Over Drug Pricing And A Controversial Drug Discount Program
The controversial 340B drug discount program for hospitals came under fire at a congressional hearing.
Many COPD Patients Struggle To Pay For Each Medicinal Breath
One in 9 Medicare enrollees have COPD and many of them can’t afford the inhalers that keep them out of the emergency room.
Drug Rebates Reward Industry Players — And Often Hurt Patients
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
Louisiana Proposes Tapping A Federal Law To Slash Hepatitis C Drug Prices
Several public health officials endorse using a federal law to slash hepatitis C drug prices in Louisiana and avoid drug bills that could cripple the state budget.
